TY - JOUR
T1 - Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis
AU - McAuliffe, Priscilla
AU - Meric-Bernstam, Funda
AU - Mills, Gordon
AU - Gonzalez-Angulo, Ana
N1 - Funding Information:
Funding support was provided by AACR SU2C Dream Team to F. Meric-Bernstam, G.B. Mills, and Ana M. Gonzalez-Angulo; S T32 CA009599-22 to P.F. McAuliffe and F. Meric-Bernstam; and NCI 1K23CA121994-01 to Ana M. Gonzalez-Angulo.
PY - 2010/11/1
Y1 - 2010/11/1
N2 - The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway mediates multiple cellular functions critical to tumor initiation, progression, and outcomes, including growth and proliferation, metabolism, motility, migration, invasion, angiogenesis, survival, and autophagy. Tight regulation of this pathway is paramount to ensure that multiple cellular inputs are integrated for appropriate cellular outcomes. Frequent deregulation and aberrations of this pathway have been implicated in breast cancer development and progression. This review focuses on the biology of this pathway and its role in breast cancer pathogenesis. The role of therapies directed at targeting mTOR in the PI3K/Akt/mTOR pathway, which are currently being evaluated in clinical trials, will also be reviewed.
AB - The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway mediates multiple cellular functions critical to tumor initiation, progression, and outcomes, including growth and proliferation, metabolism, motility, migration, invasion, angiogenesis, survival, and autophagy. Tight regulation of this pathway is paramount to ensure that multiple cellular inputs are integrated for appropriate cellular outcomes. Frequent deregulation and aberrations of this pathway have been implicated in breast cancer development and progression. This review focuses on the biology of this pathway and its role in breast cancer pathogenesis. The role of therapies directed at targeting mTOR in the PI3K/Akt/mTOR pathway, which are currently being evaluated in clinical trials, will also be reviewed.
KW - HER2
KW - Mammalian target of rapamycin
KW - PTEN
KW - Phosphatidylinositol 3-kinase
UR - http://www.scopus.com/inward/record.url?scp=78649706942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649706942&partnerID=8YFLogxK
U2 - 10.3816/CBC.2010.s.013
DO - 10.3816/CBC.2010.s.013
M3 - Article
C2 - 21115423
AN - SCOPUS:78649706942
SN - 1526-8209
VL - 10
SP - S59-S65
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - SUPPL. 3
ER -